Paris · Pre-Seed–Late Stage · 90 people tracked
Also known as SOFINNOVA PARTNERS SAS
Find your way into Sofinnova Partners
1,869 people in our graph share verified history with the Sofinnova Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Sofinnova Partners invests in breakthrough innovations addressing major health and environmental challenges. Active across the entire life sciences value chain from seed to later-stage, it focuses on healthcare and sustainability, backing entrepreneurs transforming biopharma, medtech, digital medicine, agriculture and industrial processes with cutting-edge science. The firm operates seven investment strategies, ranging from its flagship early-stage biopharma/medtech Capital fund to in-house accelerators (MD Start, Biovelocita), a Crossover growth-stage fund, an Industrial Biotech strategy spanning agriculture, chemicals, food and materials, the Telethon strategy focused on Italian science, and a Digital Medicine strategy at the intersection of biology, data and computation. It emphasizes long-term 'Partners for Life' relationships built on trust.
Source: firm website, verified Sep 15, 2026.
Team · 90 people
from the firm's website & curated & public directories
Founder mafia
The Sofinnova Partners mafia →11 people who came through Sofinnova Partners went on to found or lead other companies.
What they invest in
from 111 of 180 portfolio companiesBiotech ×88Healthtech ×60Medical Devices ×43AI & Machine Learning ×23Deep Tech ×21Digital Health ×13New Materials ×12Cleantech ×8
HQs:United States×35France×17United Kingdom×7Italy×6Netherlands×2Sweden×2
Who they back
founder profiles across 43 portfolio companiesFounding team size:solo founder×182 founders×183 founders×34+ founders×4
Where their founders studiedfrom 43 founders with education data
INSEAD ×3Pierre and Marie Curie University ×3University of Chicago ×3Columbia University ×2École Polytechnique ×2Fashion Institute of Technology ×2Northwestern University ×2Stanford University Graduate School of Business ×2
What their founders studiedfrom 44 founders with field-of-study data
Life Sciences ×17Engineering ×13Business & Management ×8Medicine ×7Finance & Accounting ×6Computer Science ×5Mathematics & Statistics ×4Chemistry ×2
Where their founders worked beforefrom 50 founders with career history
University of Colorado Boulder ×3AFYREN NEOXY ×2CHUV | Lausanne university hospital ×2Dbv Technologies ×2Ecole Polytechnique ×2IRB Barcelona ×2Sanofi ×2Stanford University ×2
25 founders hold a PhD · 9 hold an MBA (of 47 with degree data)
Investments · 180 tracked
founders shown can be your intro pathBy year:2026 · 52025 · 132024 · 92023 · 122022 · 112021 · 112020 · 72019 · 52018 · 42017 · 12016 · 52015 · 288 dated
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BiotechHealthtechGeneva
Roger Mills(Executive Officer, Director)inMikhail Kalinichev(Executive Officer)inJean-Philippe Rocher(Executive Officer)inRobert Lutjens(Executive Officer)inTimothy Dyer(Executive Officer, Director)Vincent Lawton(Director)
Co-investorsNew Enterprise Associates (NEA)ACORN BIOVENTURESSR One Capital Management
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyAvoro Capital AdvisorsHealthCapNovo HoldingsAvoro VenturesRA Capital
MaxCyte develops non-viral electroporation and cell-engineering technology used to transfect and engineer cells for research and therapeutic development.
BiotechDeep TechMedical DevicesGaithersburg, US
Douglas A. Doerfler(Executive Officer, Director)Madhusudan V Peshwa(Executive Officer)Ronald E. Holtz(Executive Officer, Director)Thomas Ross(Executive Officer)Karen Donato(Executive Officer)
BoardWilliam Brooke(Director)
Quince Therapeutics is a biotechnology company developing the AIDE technology platform, a drug/device combination that encapsulates medications into a patient's own red blood cells to improve drug delivery for rare diseases.
BiotechSouth San Francisco, US
Stephen Dominy(Director)Casey Lynch(Executive Officer, Director)Charles Ryan(Executive Officer)inBrendan Hannah(Executive Officer)Dirk Thye(Executive Officer, Director)inKristen Gafric(Executive Officer)
Co-investorsForesite CapitalTakeda Ventures
6WIND is a technology company focused on internet and telecommunications infrastructure, backed by major investors including NVIDIA and Cisco.
Cloud ComputingCybersecurityData & InfrastructureEnterprise SoftwareMontigny-le-Bretonneux, FR
Julien Dahan(Chief Executive Officer)in
Co-investorsCisco InvestmentsInnovation CapitalNVIDIA
Biotech
Co-investorsKurma PartnersJohnson & Johnson Innovation – JJDCM VenturesSR One Capital ManagementEQT Life Sciences
ASSIA develops core technology for broadband internet access and network optimization, serving telecommunications service providers and network operators.
AI & Machine LearningCloud ComputingData & InfrastructureDeep TechEnterprise SoftwareRedwood City, US
John M. Cioffi(CEO and Chairman of the Board)inAssia Cioffi(Executive Vice President and Co-founder)in
Co-investorsDTCPSofinnova VenturesStanford UniversitySwisscom VenturesPartners for GrowthPartners for Growth (PFG)
BioCorteX develops personalized therapeutics using a microbiome knowledge graph and proprietary biology emulation platform to tailor drug treatments for diverse populations.
AI & Machine LearningBiotechDigital HealthMedical Devices
Co-investorsHoxton VenturesDraper Associates
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSanofi VenturesVIVES PartnersApollo Health VenturesSixty Degree Capital
Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersQuan CapitalAstellas Venture Management LLCEMBL VenturesFuture Planet CapitalAvlar BioVentures+1 more
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.
BiotechHealthtechMedical DevicesLondon, GB
Emma Tinsley(Founder & former CEO (now Non-Executive Director))inMai-Britt Zocca(CEO)in
Co-investorsMonograph Capital PartnersForbion
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsIndaco Venture PartnersRoche Venture FundAbbVieJDRF T1D Fund
Enyo Pharma is a biotechnology company focused on drug development in the life sciences and therapeutics field.
BiotechHealthtechMedical DevicesLyon, FR
Jacky Vonderscher(Co-founder & CEO)inLaurène Meyniel-Schicklin(Founder, Head of Bioinformatics)inBenoît de Chassey(Founder, Head of Drug Discovery Platform)inPatrice André(Founder, Medical Advisor)inVincent Lotteau(Founder, Advisor)Jean-Jacques Garaud(Co-founder)in
Co-investorsAndera PartnersOrbiMedBpifrance
Excelsior Sciences develops automated chemistry technology for small-molecule discovery and manufacturing, targeting pharmaceutical and materials development.
AI & Machine LearningBiotechDeep Tech
Marty BurkeBartosz GrzybowskiMichael Foley(CEO)inJana Jensen(COO)in
Co-investorsKhosla VenturesCornucopian Capital ManagementIllinois VenturesDeerfield Management Company
Genespire is a life sciences company backed by multiple venture capital investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners.
BiotechDeep TechDigital HealthHealthtech
Dr. Lucia Faccio(Chief Executive Officer)inDr. Julianne Smith(Chief Development Officer)Dr. Simon Hawkins(VP Clinical Development)Dr. Smaragda Angelidou(Responsabile CMC)Dr. Mary Wang(Patient Engagement Director)Emanuela Balzo(VP of Finance)in
Co-investorsCDP Venture CapitalIndaco Venture PartnersXGEN Venture
HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.
AI & Machine LearningBiotechDeep TechHealthtech
Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)inDaniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in
Co-investorsBroadview VenturesApollo Health Ventures+ND Capital4see VenturesHumboldt
HighLife develops a transcatheter mitral valve replacement (TMVR/TSMVR) technology for patients with moderate to severe mitral regurgitation, implanted in a beating heart while preserving the native valve structure.
BiotechHealthtechMedical DevicesParis, FR
Georg Börtlein(Founder)inMalek Nasr(Founder)inRüdiger Lange(Founder (Heart Surgeon))Nicolo Piazza(Founder (Interventional Cardiologist))Stefan Pilz(CEO)inStephen Brecker(Chief Medical Officer)in
Co-investorsAndera PartnersUS Venture PartnersVI Partners
Home Biosciences was a venture builder in Continental Europe dedicated to creating and scaling biotech companies through an asset-centric, hub-and-spoke model, working with academics and scientists on drug discovery and molecular profiling projects.
AI & Machine LearningBiotechHealthtech
David Schilansky(Co-founder & Non-executive Chairman)inMagali Richard(Co-founder)in
Co-investorsREDMILE
Inspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform.
BiotechHealthtechMedical DevicesNew York, US
Sohail Tavazoie(Co-Founder & Chair of Scientific Advisory Board)Masoud Tavazoie(Co-Founder & Advisor)in
Co-investorsVivo CapitalSands Capital VenturesStart CapitalNovo Holdings
Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors.
BiotechHealthtechLondon, GB
John Maher(Founder)
Co-investorsVulpes Investment ManagementEpidarex Capital
May Health develops medical technology solutions for women with polycystic ovary syndrome and PCOS-related infertility.
FemTechHealthtechMedical DevicesParis, FR
BoardColby HoltshouseHugh E. Magen
Co-investorsBpifrance
Microphyt develops microalgae-based ingredients and products for nutrition, dietary supplements, and personal care using proprietary bio-reactor technology.
BiotechFoodTechHealthtechNew MaterialsWellness & Fitness
Arnaud Muller-FeugaVincent Usache(Managing Director)in
Co-investorsBpifranceSupernova Invest
Moon Surgical develops the Maestro robotic surgery system, a digital surgical robotics platform used by surgeons to perform procedures.
HealthtechMedical DevicesRoboticsParis, FR
Brice Gayet(Founder)inAnne Osdoit(Chief Executive Officer)inEric Ermenault(Chief Commercial Officer)inAnne Renevot(Chief Financial Officer)inViola Fleig(Chief Operations Officer)inDavid Noonan(Chief Technology Officer)in
Co-investorsNVIDIACathay HealthJohnson & Johnson Innovation – JJDCNVentures
NanoPhoria is a life sciences company that raised an €83.5 million Series A round.
BiotechDeep TechMedical Devices
Daniele CatalucciinMichele IafiscoAlessio AlognaClaudio De Lucain
Co-investorsXGEN VentureCDP Venture CapitalEuropean Innovation Council Fund
Nuage Therapeutics develops drug discovery technologies for disordered proteins, focusing on precision treatments for aggressive cancers with limited therapeutic options.
AI & Machine LearningBiotechDeep TechBarcelona, ES
Mateusz Biesaga(Founder and Chief Technology Officer)inXavier Salvatella(Founder)in
Co-investorsAsabys PartnersBStartup
Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.
BiotechDigital HealthHealthtechMedical Devices
Moin Saleem(Co-founder & Chief Scientific Advisor)in
Co-investorsForbionGilde HealthcareAdvent Life SciencesBritish Patient Capital
SafeHeal is a medical device manufacturer developing anastomosis protection devices for colorectal surgery.
BiotechDigital HealthHealthtechMedical DevicesFrance, FR
Chris Richardson(President & CEO)inKarl Blohm(VP, International)inScott DePierro(VP, US Operations)inMarcos Velez-Duran(VP, Regulatory Affairs and Quality)inBrent Metzler(CFO)Michael Augelli(VP, R&D, Manufacturing)in
Co-investorsAsabys Partners
Sitryx is a biotechnology company, founded in 2018, developing therapeutics with a focus on immunometabolism.
BiotechDeep TechHealthtech
Co-investorsLongwood FundOxford Science EnterprisesSV Health Investors
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)inSteve Anheier(Executive Officer)in
BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)in
Board seatAntoine Papiernik Papiernik· per SEC Form D
Co-investorsNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLCJanus Henderson Investors+2 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Board seatMaina Bhaman· per SEC Form D
Co-investorsAgent CapitalLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture Investments+3 more
RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.
BiotechHealthtechMedical DevicesHayward, US
Samuel Mazin(Executive Officer, Director)inAkshay Nanduri(Executive Officer, Director)in
BoardJay Watkins(Director)in
Board seatAntoine Papiernik Papiernik· per SEC Form D
Co-investorsAscension VenturesCatalio Capital Management, LPPfizer Venture InvestmentsSonder CapitalVenrockSonder Futures
BiotechNew York, US
Masoud Tavazoie(Chief Scientific Officer)David Darst(Chief Operating Officer)Isabel Kurth(Vice President - Research)
BoardShahram Seyedin-Noor(Executive Chairman)Nancy Chang(Director)
Board seatAntoine Papiernik Papiernik· per SEC Form D
Co-investors+ND CapitalOceanpine Capital
Shockwave Medical develops intravascular lithotripsy (IVL) catheter systems used to treat calcified cardiovascular disease, marketed to interventional cardiologists and vascular specialists.
HardwareHealthtechMedical DevicesFremont, US
Daniel Hawkins(Executive Officer, Director)inTodd J. Brinton(Director)inIsaac(President)
BoardJay Watkins(Director)inAntoine Papiernik(Director)inFrederic H. Moll(Director)
Board seatAntoine Papiernik Papiernik· per SEC Form D
Co-investorsSonder CapitalVenrockSectoral Asset Management
Co-investorsNeva Sgr.XGEN VentureAtlas VentureForbionLongwood Fund
ABIONYX Pharma is a biotech company developing therapies for diseases with no effective or existing treatment, including rare conditions.
Biotech
Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
BiotechHealthtechMedical DevicesParis, FR
Marc de Garidel(CEO)in
Co-investorsAndera PartnersClaret Capital PartnersMedicxiSamsara BioCapitalTruffle CapitalMorgan Stanley
Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Darshan Dalal(Chief Medical Officer)in
Co-investorsHadean VenturesM Ventures4BIO CapitalBioqube Ventures
Afyren produces bio-based organic acids derived from fermentation of non-food biomass to replace petroleum-derived molecules in consumer products and industrial applications.
BiotechCircular EconomyCleantech
Nicolas Sordet(Co-founder)inJérémy Pessiot⚡(Founder)in
Co-investorsSupernova Invest
Alia Therapeutics is a biotech company developing therapeutics based on gene-editing technology.
BiotechDeep TechHealthtech
Co-investorsIndaco Venture Partners
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersM VenturesNovartis Venture FundPfizer Venture InvestmentsRA CapitalSV Health Investors+2 more
Arzeda designs proteins and metabolic pathways using computational tools, including its Archytas protein design software and Scylax metabolic pathway design software.
AI & Machine LearningBiotechDeep TechFoodTechNew MaterialsSeattle, US
Alexandre Zanghellini(Co-Founder & Chief Executive Officer)inEric Althoff(Executive Officer, Director, Promoter)inDavid BakerBill Baum(Director)inAndrew Ban(Executive Officer)Daniela Grabs(Executive Officer)
Co-investorsCirculate CapitalSustainable Conversion VenturesContinental Grain CompanyFall Line CapitalLewis & Clark AgriFoodOS Fund+1 more
Avantium develops bio-based materials and polymer technologies, including PEF and other renewable alternatives to conventional plastics, serving the packaging and materials industry.
BiotechCircular EconomyCleantechNew MaterialsNetherlands, NL
Co-investorsNavitas CapitalAster CapitalCapricorn Venture PartnersNV NOMPMVSignet Healthcare Partners+2 more
BioClec is a Milan-based discovery-stage biotech developing microglia-targeting therapies for Alzheimer's disease and dementia, launched from Sofinnova Partners' Biovelocita II accelerator.
Milano, IT
Bioptimus is an AI-first biotech company developing a universal AI foundation model that connects biology across scales, from molecules and cells to tissues and whole organisms, to support biomedical research and innovation.
AI & Machine LearningBiotechDigital HealthHealthtechParis, FR
Eric Durand(Founder)inFelipe Llinares-López(Co-founder & VP of AI)inRodolphe Jenatton(Co-founder & CTO)inZelda Mariet(Co-founder & VP of Research)inJean-Philippe Vert(Co-founder & CEO)inDavid Cahané(Co-founder & General Manager)
Co-investorsAndera PartnersCathay InnovationFELIX CAPITALFrstHeadlineHeadline Growth Management, LLC+3 more
Biosyntia is a Copenhagen-based industrial biotech company that uses strain engineering and fermentation to produce sustainable, bio-based active ingredients like vitamin B7, replacing petrochemical-derived alternatives for cosmetics and nutrition markets.
Copenhagen, DK
Co-investorsEuropean Circular Bioeconomy FundNovo Holdings
Biotalys develops protein-based biocontrol products for crop protection, giving farmers tools to prevent crop loss and extend post-harvest protection while reducing food waste.
AgTechBiotechFoodTechGhent, BE
Co-investorsAgri Investment FundPMV
Borea Therapeutics develops gene therapy delivery technologies based on a proprietary AAV conjugation platform targeting neurological and genetic diseases.
BiotechDeep TechHealthtechMedical Devices
Paul Heppenstall(Scientific Co-Founder)Niccolò Bacchi(CEO)in
BrightHeart develops the B-Right AI Platform, an AI system that analyzes routine prenatal ultrasound images and clips to help clinicians and sonographers detect signs of congenital heart defects and confirm fetal heart scan completeness.
AI & Machine LearningDigital HealthHealthtech
Co-investorsLLR
Calliditas is a biopharmaceutical company developing and commercializing treatments for renal and other conditions, including TARPEYO/Nefecon/Kinpeygo (budesonide) for primary IgA nephropathy and NOX inhibitor candidates such as setanaxib for fibrotic diseases and cancer.
BiotechHealthtechMedical DevicesStockholm, SE
Co-investorsIndustrifondenKreos Capital
Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering.
BiotechHealthtech
Branden Moriarity(Scientific Co-founder)Catherine Bollard(Scientific Co-founder)
Co-investorsAstellas Venture Management LLCLightstone Ventures
CelluComp develops sustainable, cellulose-based bio-composite materials for packaging applications, serving consumer goods and packaging companies seeking environmentally responsible alternatives.
Advanced ManufacturingCircular EconomyCleantechNew MaterialsScotland, GB
Dr. Eric Whale(Founder and Head of Technology)Dr. David Hepworth(Founder)Christian Kemp-Griffin(CEO)in
.jpg/fit-in/500x500/filters:no_upscale())
Co-investorsScottish Enterprise
Cambridge, US
ENEJ KUSCER, PH.D.(Executive Officer)PETER VAN VLASSELAER, PH.D.(Director)HENRIJETTE RICHTER, PH.D.(Director)BERNARDUS MACHIELSE(Director)LUCAS DE BREED(Director)DAVID DE GRAAF, PH.D.(Executive Officer, Director)
Co-investorsMission BiocapitalCanaan Partners
CorVent Medical develops medical ventilators, including the RESPOND ventilator, that provide ICU-standard respiratory support for acute and post-acute patients.
HardwareHealthtechMedical DevicesFargo, US
Murphy Travis(Executive Officer)inJeremy Nelson(Executive Officer)inRichard S. Walsh(Executive Officer, Director)inJohn O'Mahony(Executive Officer)inRob Faulkner(Director)Lukas Geunther(Director)
CorWave produces a ventricular assist pump for advanced heart failure patients, delivering pulsatile flow to provide mechanical cardiac support for transplant candidates, non-transplant-eligible patients, and recovery cases.
BiotechDeep TechHealthtechMedical Devices
Louis de Lillers(CEO)inAndreas Fleischli(CTO)in
Co-investorsYsios Capital
Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform.
AI & Machine LearningBiotechDigital HealthHealthtech
Paloma Cejas(Founder, Head of Translational Research)inRémy Nicolle(Founder, Senior Advisor Computational Biology)
Co-investorsHitachi VenturesKima VenturesLifeX Ventures
An AI radiology platform that automates the reporting process and hosts 80+ leading imaging AI vendors.
Co-investorsMeridian Health Ventures
DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols.
BiotechClimate TechNew MaterialsBoulder, US
Matthew Lipscomb(Director)Josh Yelen(Executive Officer)Jim Flatt(Executive Officer, Director)in
BoardJosko Bobanovic(Director)Rob van der Meij(Director)inAlastair Cooper(Director)
Co-investorsBreakthrough Energy VenturesBoulder VenturesCapricorn Venture Partners
Elicit Plant develops agricultural solutions that trigger plants' natural defenses to help field crops resist water stress and adapt to climate change.
AgTechBiotechClimate Tech
Olivier Goulay(Founder)in
Co-investorsEuropean Circular Bioeconomy Fund
Endoron Medical develops transcatheter anchoring and sealing devices for aortic procedures, including Aortodock (a nitinol docking system to stabilize transcatheter valves in low-calcium aortic regurgitation and stenosis anatomies) and Aortoseal (a multi-stapling fixation and sealing system for endovascular aneurysm repair grafts).
HardwareHealthtechMedical Devices
Enginzyme develops a technology platform for sustainable chemistry applications aimed at removing carbon dioxide from the atmosphere.
BiotechCleantechClimate TechNew MaterialsStockholm, SE
Aymeric de Gantès(CEO)inJosefin Lannefors(Chief Commercial Officer)inMarco Antonio Saucedo(Chief Technology Officer)in
Co-investorsIndustrifondenNavigare Ventures
Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.
Advanced ManufacturingBiotechFoodTechNew Materials
Will Milligan(CEO & Founder)in
Co-investorsBig Idea VenturesFFFNewland SyndicateUnruly Capital5AM VenturesAgent Capital+8 more
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSunstone Capital+3 more
Forth Therapeutics is an Edinburgh/Cambridge-based biotech spinout from the University of Edinburgh developing precision, omics-driven therapeutics to halt or reverse fibrosis across multiple organ systems.
Co-investorsOld College Capital
Freya Biosciences develops innovative therapies targeting immune-mediated diseases that affect women.
BiotechFemTechHealthtech
Colleen Acosta, PhD(CEO, Co-Founder)Johan van Hylckama Vlieg, PhD(CSO, Co-Founder)
Co-investorsAngelini VenturesIndaco Venture PartnersOMX VenturesBill & Melinda Gates Foundation
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)in
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge GroupCatalyst InvestorsFidelity Investments+5 more
Galvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy.
CleantechClimate TechEnergy
Veery Maxwell(Founder)in
Co-investorsABS Capital PartnersBlue Haven InitiativeGalvanize Climate SolutionsAlly Bridge GroupFidelity InvestmentsGilmartin Capital LLC+4 more
GenSight Biologics develops clinical-stage gene therapy treatments, with a lead candidate (GS010/LUMEVOQ) in development for rare genetic diseases.
BiotechDigital HealthHealthtechMedical DevicesParis, FR
Jean-Philippe Combal(Executive Officer)Michael Stephen Wyzga(Director)Thomas Gidoin(Executive Officer)Didier Pruneau(Executive Officer)Florent Gros(Director)Nitza Thomasson(Executive Officer)
Co-investorsAbingworth
GFBiochemicals develops plant-based chemical ingredients derived from levulinate technology to replace harmful petrochemical components in consumer products such as shampoos, detergents, and cosmetics.
BiotechCircular EconomyCleantechClimate TechNew MaterialsAix en Provence, FR
Mathieu Flamini(Founder)inPasquale Granata(Founder)in
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalAgent Capital+1 more
HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.
AI & Machine LearningBiotechHealthtech
BoardBruce Booth(Chairman)in
Co-investorsAtlas VentureB Capital GroupB4 CapitalMRL Ventures FundSolasta VenturesSR One Capital Management+1 more
.jpeg){kind=logo}
Ingenix builds an AI "Reasoning Engine" using an approach it calls Modality Fusion to integrate biological data across modalities and scales.
AI & Machine LearningBiotechDeep Tech
Adam Dancewicz(Founder)
Co-investorsInovo VCOTB VenturesIFC
Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.
BiotechMedical Devices
Co-investorsEuropean Investment BankAndera PartnersClaret Capital PartnersNew Enterprise Associates (NEA)Samsara BioCapitalBiotechnology Value Fund+1 more
iOmx Therapeutics is a biotech company developing novel cancer therapies.
AI & Machine LearningBiotechHealthtechMedical DevicesMunich, DE
Co-investorsM VenturesMIG Capital AG
Julier Medical is a Paris-based, pre-clinical medical device startup developing a mechanical thrombectomy device to remove blood clots and restore blood flow in acute ischemic stroke patients.
The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.
HealthtechImpact & Social Good
Co-investorsYsios CapitalBioGeneration VenturesEpidarex CapitalRoche Venture FundScottish National Investment Bank
Kiro is a health technology company that transforms healthcare data into actionable intelligence for patients and healthcare providers.
AI & Machine LearningDigital HealthHealthtech
Co-investorsKima Ventures
Latent Labs develops generative AI models for protein design and builds biological platforms to validate AI-driven designs.
AI & Machine LearningBiotechDeep TechLondon, GB
Simon Kohl(CEO / Team Lead)in
Co-investors8VCFlying Fish VenturesIsomer CapitalKindred CapitalPillar VCRadical Ventures
LimFlow develops a medical device system for the treatment of chronic limb-threatening ischemia.
HealthtechMedical Devices
Co-investorsLongitude Capital
HealthtechPlymouth, US
Dan Sachs(Director)Peter Crosby(Executive Officer, Director)inJason Hannonin
BoardManus Rogan(Director)inAntoine Papiernik(Director)in
Co-investorsFountain Healthcare PartnersAlly Bridge GroupGilde HealthcareViking Global Investors
Meiogenix develops a proprietary recombination technology that targets meiotic recombination to accelerate genetic gain and variety development in crops.
AgTechBiotechDeep Tech
Ricardo Garcia de Albain
Co-investorsGenoa VenturesKurma PartnersCasdin Capital
Micropep develops natural crop protection solutions using micropeptides—short protein molecules that regulate plant genes and proteins—for farmers seeking sustainable alternatives.
AgTechAI & Machine LearningBiotechClimate TechToulouse, FR
Thomas Laurent(Founder & Strategic Advisor)inGeorg Goeres(Chief Executive Officer)inMikael Courbot(Chief Technology Officer)in
Co-investorsSupernova InvestFall Line CapitalZebra Impact Ventures
Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.
BiotechMedical Devices
Adele Rowley(Chief Scientific Officer)in
Co-investorsEpidarex CapitalRoche Venture FundBioGeneration VenturesScottish National Investment Bank
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
Co-investorsPfizer Venture InvestmentsRoche Venture FundSR One Capital Management
Mnemo Therapeutics is a Paris-based clinical-stage biotech developing cell therapies using its EnfiniT epigenetic antigen discovery platform to target tumor-specific antigens for CAR-T therapies.
Co-investorsAlexandriaCasdin CapitalREDMILE
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsAlexandria+4 more
Muna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.
BiotechDeep TechHealthtechLongevity
Rita Balice-Gordon(Founder)inJoachim Vilstrup(Head of Protein Chemistry and Structural Biology; scientific co-founder)inMichel Detheux(Chief Executive Officer & Board Director)inAnders Hinsby(Chief Operating Officer)inNiels Plath(Chief Scientific Officer)inJakob Busch-Petersen(Chief Development Officer)in
Co-investorsDroia VenturesSanofi VenturesV-Bio Ventures
Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment.
BiotechMedical DevicesLondon, GB
Co-investorsBrandon Capital PartnersNovo HoldingsAbingworth
Nephris is a biotech company developing first-in-class therapies for diabetic chronic kidney disease.
BiotechDigital Health
Neurent Medical develops the NEUROMARK system, a radiofrequency ablation device that targets hyperactive autonomic nerves to treat chronic rhinitis symptoms in ENT patients.
HealthtechMedical Devices
Co-investorsAtlantic Bridge VenturesClaret Capital PartnersMVM Life Science PartnersEnterprise IrelandEQT Life SciencesFountain Healthcare Partners+1 more
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsMission BiocapitalAbbVieDementia Discovery FundMission Bay Capital
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)inChris Guiffre(Executive Team)inAlan P. Watt(Executive Team)inJyothis George(Chief Medical Officer)inNick Clarke(Executive Team)in
Co-investors5AM VenturesEpidarex CapitalF-Prime CapitalSanofi Ventures
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersJeito CapitalRoche Venture FundEQTEQT Life SciencesForbion+2 more
NovaMeat develops plant-based protein food products, positioning them as part of a new culinary tradition.
FoodTech
Giuseppe Scionti(Founder)in
Co-investorsAurum Venture PartnersCarbonUnovis Asset ManagementVU Venture PartnersForbionRubio Impact Ventures
The page is a Vietnamese-language sports streaming site (90Phut TV / 90Phutr.tv, also called Vaoroi TV) offering free live football streaming links, match schedules, standings, results, news, and betting odds.
Media & EntertainmentSports TechHà Nội, VN
Co-investorsAisling CapitalM VenturesNew Enterprise Associates (NEA)Sofinnova Ventures
BiotechPrinceton, US
Gerald Wisler(Executive Officer, Director)Christian Schade(Executive Officer)
BoardGraziano Seghezzi(Director)inDavid Mott(Director)George Horner(Director)
Co-investorsNew Enterprise Associates (NEA)
P2 Science develops green chemistry platform technologies (including its PIOz ozonolysis and PICE polymerization processes) that convert renewable, plant-based oils into functional intermediates, specialty ingredients, and polymers.
BiotechCircular EconomyCleantechNew MaterialsWoodbridge, US
Paul Anastas(Co-founder)Patrick Foley(Co-founder & President)inNeil A. Burns(Executive Officer, Director)Oihana Elizalde(Chief Executive Officer)inBrian Chan(Chief Financial Officer)inKevin Gallagher(Director)
Co-investorsXeraya CapitalCircular Innovation FundConnecticut InnovationsEmerald Technology Ventures AgHG VenturesSafer Made+1 more
Pi-Cardia develops non-implant-based, catheter-delivered devices for treating structural heart disease, including its ShortCut product for leaflet modification.
HardwareHealthtechMedical Devices
Erez Golan(Founder)in
Co-investorsAccelmed PartnersClal Biotechnology IndustriesIndaco Venture Partners
PinCell is a biotech company developing pharmaceutical treatments in the field of dermatology, based on research into skin biology and skin disorders.
BiotechMedical Devices
Carlo Pincelli(CMO, Co-Founder, Co-Inventor)inAlessandra Marconi(Co-Founder, Co-Inventor)inAntonino Amato(Chairman & CEO)inBrydon Bennett(CSO)in
Prometheus Materials develops low-carbon cement and concrete technology, marketed as ProZERO, using algae-based biotechnology as a replacement for portland cement in ready-mix and construction applications.
CleantechConstruction TechNew MaterialsLongmont, US
Loren Burnett(President, CEO and Co-founder)inSherri Cook(Advisor and Co-founder)inMija Hubler(Engineering Advisor and Co-founder)inWil Srubar III(Technology Advisor and Co-founder)inJaclyn Gruber(Chief Marketing Officer)in
BoardJosko Bobanovic(Director)
Co-investorsAutodesk Foundation
ProQR develops medicines for patients with unmet medical needs, focusing on therapeutic development in biotech.
BiotechHealthtechMedical DevicesLeiden, NL
Co-investorsInvivo Capital PartnersPontifax Venture Capital
Protera builds functional protein ingredients for the food industry using its madi platform, which combines generative AI and computational biology to design novel proteins produced through precision fermentation.
AI & Machine LearningBiotechFoodTech
Co-investorsSOSV
Qorium develops cell-cultured leather grown from a single animal cell sample, producing uniform collagen sheets that integrate into existing tannery and leather-goods production processes.
BiotechCircular EconomyNew Materials
Co-investorsBrightlands Venture PartnersInvest-NL
Recor Medical develops the Paradise Ultrasound Renal Denervation system, a therapy that uses ultrasound technology to lower blood pressure in patients with hypertension.
BiotechHardwareHealthtechMedical DevicesPalo Alto, US
Jacques Seguin(Director)in
BoardAndrew M. Weiss(Executive Officer, Director)Antoine Papiernik(Executive Officer, Director)inKazumichi Kobayashi(Director)F. Thomas Watkins(Director)Frank Litvack(Director)
Co-investors415 Capital
Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology.
AI & Machine LearningBiotechBoston, US
George Daley(Co-founder)Richard Gregory(Co-founder)Frank Slack(Co-founder)Piotr Sliz(Co-founder)inKazumi Shiosaki(President & CEO)in
Co-investorsAstellas Venture Management LLCOUP (Osage University Partners)
Provides pharmaceutical R&D services via the Cyto-Mine machine for single-cell analysis and characterisation.
Co-investors24 HaymarketQVenturesProvidence Investment Company LimitedREDMILE
Synthace provides a software platform for experimental design and lab automation, enabling researchers to run Design of Experiments (DOE) workflows across multiple automated laboratory instruments and devices.
AI & Machine LearningBiotechCloud ComputingDeep TechSaaS
Markus Gershater, PhD(Chief Executive Officer & Co-Founder)
Co-investors11.2 CapitalFuture Planet CapitalHorizons VenturesUK Innovation & Science Seed FundAmadeus Capital PartnersSOSV
T-Therapeutics develops T cell receptor-based therapeutics for cancer and autoimmune diseases using its proprietary OpTiMus platform, which identifies antigen-specific human TCRs.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, GB
Co-investorsCambridge Innovation CapitalF-Prime CapitalSanofi VenturesDigitalis Ventures
Tenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye.
BiotechDigital HealthHealthtechLongevityMedical DevicesWarren, US
HENRIC BJARKE(Chief Executive Officer)in
Co-investorsAdBio partnersF-Prime Capital
TISSIUM develops biomorphic polymer technology, including proprietary polymers, activation technologies, and delivery devices, to reconstruct damaged tissue and restore its function across multiple therapeutic areas.
BiotechDeep TechMedical DevicesNew Materials
Christophe Bancel(Co-founder & CEO)inMaria Pereira(Co-inventor of the technology; leads the Innovation Hub)in
Co-investorsCathay HealthKaristaEuropean Investment BankOmnes Capital
Tulyp Medical develops the Tulyp System, an investigational pressure-controlled perfusion device with a microaxial pump cannula designed to restore blood flow to the leg in patients on femoral arterial support (VA-ECMO, IABP, pVAD) who are at risk of acute limb ischemia.
HardwareHealthtechMedical Devices
A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.
BiotechSan Diego, US
David Johnson(Executive Officer, Director)Cam Gallagher(Director)Scott L. Glenn(Director)in
Co-investorsChiesi VenturesPappas CapitalSofinnova VenturesVedanta CapitalArix BioscienceOrbiMed
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)inPeter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more
Women-led biotech company engineering high-performance protein-based textile fibers for fashion with sustainable alternatives to synthetic fibers.
BiotechBrooklyn, US
Valentina Gomez(Executive Officer, Director)inTheanne Schiros(Executive Officer)Chui-lian Lee(Founder)in
BoardCorinna Chen(Director)inMichael Krel(Director)in
Co-investorsMaterial Impact
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Corvidia TherapeuticsHookipa PharmaAblynx NvAdvanced Perfusion DiagnosticsAmolyt PharmaAutolusBetteromicsBiovelocitaBiovelocita Signadori BioBreath TherapeuticsCapital Ascendis PharmaCapital CinCor PharmaCapital DBVCapital EOSCapital GensetCapital Innate PharmaCapital Myricx BioCapital NuCanaCapital Pi-CardiaCapital T-TherapeuticsCapital TissiumCapital VectivBioCardiaCellcentricCinCor PharmaComet BioComet BiorefiningCoreValveCrossover Neurent MedicalCrossover Redx PharmaCrossover Verona PharmaDeliniaDigital Medicine Cure51Digital Medicine Excelsior SciencesDigital Medicine L'école AIDisco PharmaceuticalsDna ScriptEnobraQEnthera PharmaceuticalsEOSGlycovaxynGradient Denervation TechnologiesHepta MedicalHighlifeHotspotInotremLysogeneMablink BioscienceMetgenMovetisNchroma Formerly Chroma MedicineNitrome BiosciencesNovexelNoxxon Pharma AgPixiumPixium VisionPrecardiaPregLemPyrowaveQuince Therapeutics Formerly ErydelVectivBioVerleyVerley Formerly Bon Vivant
Exits · 16
4 IPOs · 12 acquisitions · showing 15Addex TherapeuticsNASDAQ: ADXNHemab TherapeuticsNASDAQ: COAGMaxcyteNASDAQ: MXCTQuince TherapeuticsNASDAQ: QNCXAblynx Nvacq. by SanofiAdvanced Perfusion Diagnosticsacq. by VygonBetteromicsacq. by AppleBreath Therapeuticsacq. by ZambonCoreValveacq. by MedtronicDeliniaacq. by CelgeneGlycovaxynacq. by GlaxoSmithKlineMovetisacq. by ShireNovexelacq. by AstraZenecaPixiumacq. by Science CorporationPrecardiaacq. by Abiomed
Portfolio news
latest coverage across their companiesSensorion · endpoints.news · Sep 16, 2026
Cardia · financial-news.co.uk · Sep 1, 2026
Tenpoint Therapeutics · ophthalmologytimes.com · Aug 30, 2026
Inventiva · themarketsdaily.com · Aug 26, 2026
Galvanize · muonspace.com · Aug 20, 2026
ProQR · investing.com · Aug 20, 2026
Biotalys · manilatimes.net · Aug 20, 2026
Frequently asked questions
- How many investments has Sofinnova Partners made?
- Sofinnova Partners has 180 tracked investments, 16 of which have exited, including 19 dated in the last 24 months.
- What stage does Sofinnova Partners invest at?
- Sofinnova Partners invests at the Pre-Seed, Seed, Series A, Series B, Growth, Late Stage stages.
- What is Sofinnova Partners's typical check size?
- Sofinnova Partners typically writes checks of $540K – $27M.
- What sectors does Sofinnova Partners focus on?
- Sofinnova Partners focuses on AgTech, Biotech, Cleantech, Climate Tech, Deep Tech, Digital Health, FoodTech, Healthtech, Impact & Social Good, Longevity, Medical Devices, New Materials.
- Where is Sofinnova Partners located?
- Sofinnova Partners is headquartered in Paris, FR.
- Does Sofinnova Partners lead rounds?
- Yes, Sofinnova Partners leads investment rounds.
- Who does Sofinnova Partners co-invest with?
- Sofinnova Partners most often shares deals with Andera Partners, Indaco Venture Partners, Pfizer Venture Investments, among 146 tracked co-investors.
Media · Podcasts & interviews
featuring the teamAntoine Papiernik, Chairman of Sofinnova Partners, on Venture Capital in MedTech
State of MedTech · Antoine Papiernik
Images
Co-investors · 41
M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
▶29 more co-investors
Kurma PartnersSV Health InvestorsLongwood FundNorwest Venture PartnersSOSVOrbiMedBioGeneration VenturesApollo Health VenturesSonder CapitalAbbVieAccess BiotechnologyCanaan PartnersUS Venture PartnersARCH Venture PartnersAtlantic Bridge VenturesCambridge Innovation CapitalDigitalis VenturesLightstone VenturesLeaps by BayerWestlake Village BioPartnersUnovis Asset ManagementGV (Google Ventures)MPM BioImpactPivotal Life SciencesAccess IndustriesSeventure PartnersIllumina VenturesJMI EquityAmzak Health
Firms observed investing alongside Sofinnova Partners, from public investor directories. Shared companies are the overlap with Sofinnova Partners's recorded portfolio.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner in venture and growth capital funds backing technology-focused Canadian companies. It supports emerging and established fund managers to strengthen Canada's innovation ecosystem.